PERSON – Page 26

Biotech Layoffs Continue in 2024: Spero and Pfizer Among Latest to Cut Workforce

6 months ago talkbio0Tagged Biotech Layoffs, Drug Industry, layoffs, Pfizer, Spero

Biotech layoffs, Spero, Pfizer, workforce reduction, 2024 layoffs, pharmaceutical industry, job cuts.

Biogen and Sage Discontinue Plans for Major Depressive Disorder Approval for Zurzuvae

6 months ago talkbio0Tagged Approved, Biogen, Depression, Postpartum, Depressive disorder, United States Food and Drug Administration, Zurzuvae

Biogen, Sage Therapeutics, Zurzuvae, postpartum depression, major depressive disorder, FDA approval

Eli Lilly’s Kisunla Shows Reduced Brain Swelling with Modified Dosing Regimen in Alzheimer’s Patients

6 months ago talkbio0Tagged Alzheimer 's disease, ARIA-E, Cerebral Edema, Changing, dosing, Eli, Eli Lilly, Kisunla, Risk, Treatment Protocols

Eli Lilly, Kisunla, Alzheimer’s disease, brain swelling, modified dosing regimen, ARIA-E risk reduction

Astellas Withdraws European Application for Geographic Atrophy Treatment Izervay

6 months ago talkbio0Tagged Application procedure, Astellas, avacincaptad, European (ethnic group), Geographic Atrophy, IZERVAY, pegol

Astellas, Izervay, geographic atrophy, European application withdrawal, avacincaptad pegol

Modified Dosing Regimen of Eli Lilly’s Alzheimer’s Drug Kisunla (Donanemab) Reduces Brain Swelling

6 months ago talkbio0Tagged Alzheimer 's disease, amyloid-related imaging abnormalities, ARIA-E, Cerebral Edema, Changing, Donanemab, dosing, Eli, Eli Lilly, Kisunla, oedema/effusion, TRAILBLAZER-ALZ, Treatment Protocols, Trial Phase 3B

Alzheimer’s disease, Eli Lilly, Kisunla (donanemab), Modified dosing regimen, ARIA-E (amyloid-related imaging abnormalities with oedema/effusion), Brain swelling, TRAILBLAZER-ALZ 6 Phase IIIb trial

Biopharma Industry Alarmed by Prospect of RFK Jr. Shaping FDA Policies Under Trump Administration

6 months ago talkbio0Tagged Administration occupational activities, Agriculture, Biopharma, Health care facility, Policy, RFK Jr., Transplant Registry Unified Management Program, United States Food and Drug Administration

RFK Jr., FDA, Trump Administration, Biopharma, Healthcare Policy, Agriculture Policy

Innovent’s IL-23 Drug Picankibart Shows Promising Results in Phase 3 Trial for Moderate to Severe Plaque Psoriasis

6 months ago talkbio0Tagged acceptance, Chinese Language, Clinical Trials, Dental Plaque, inhibitors, Innovent, interleukin-23, NDA, Phase 3, Phase 3, picankibart, Regulators (device)

Innovent Biologics, Picankibart, IL-23 inhibitors, Plaque psoriasis, Phase 3 clinical trial, Chinese regulators, NDA acceptance

Lilly and J&J Unveil Promising IL-23 Inhibitor Data for Crohn’s Disease, Setting Stage for FDA Decisions

6 months ago talkbio0Tagged Clinical Trials, Crohn 's disease, Decision, Eli, Eli Lilly, inhibitors, interleukin-23, Tremfya, United States Food and Drug Administration

Crohn’s disease, IL-23 inhibitors, Eli Lilly, Johnson & Johnson, Omvoh, Tremfya, clinical trials, FDA decisions.

Novartis and Monte Rosa Collaborate on $2.2B Molecular Glue Degrader Alliance

6 months ago talkbio0Tagged Biopharma, Collaboration, molecular glue, Monte Rosa, Neoplasms, Neurological diseases, Novartis, Protein Degradation, Metabolic

Novartis, Monte Rosa, molecular glue degraders, biopharma collaboration, protein degradation, oncology, neurological diseases

Novartis Invests $150M in Monte Rosa’s Molecular Glue Technology for Autoimmune Diseases

6 months ago talkbio0Tagged Autoimmune Diseases, biotech, Collaboration, molecular glue, Monte Rosa, Novartis, Protein Degradation, Metabolic, VAV1-degrader

Novartis, Monte Rosa, Molecular Glue, Protein Degradation, Autoimmune Diseases, MRT-6160, VAV1-degrader, Biotech Collaboration